The short answer: No. Compounded semaglutide is not Ozempic. Ozempic is an FDA-approved drug with a fixed formula, a tested pen, and a reviewed label. A compounded product is mixed by a pharmacy or outsourcing facility and never goes through FDA review for safety, effectiveness, or quality. Some compounded products even use a different active ingredient, a salt form that FDA says is not the same as the semaglutide in Ozempic. The legal window that allowed mass compounding of semaglutide closed in 2025.
What is a compounded drug?
Compounding is the practice of preparing a drug for a specific patient when an approved product does not fit. The FDA compounding Q&A gives the classic examples: removing an allergen, or turning a tablet into a liquid for someone who cannot swallow pills. FDA states it plainly: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."
Federal law splits compounders into two groups:
- 503A pharmacies. State-licensed pharmacies where a licensed pharmacist or physician compounds for an individual prescription. FDA notes these are not subject to current good manufacturing practice (CGMP) requirements. State boards of pharmacy oversee them.
- 503B outsourcing facilities. Created by a 2013 law. They register with FDA, pay an annual fee, and must follow CGMP. FDA inspects them on a risk-based schedule and publishes a list of registered outsourcing facilities.
Neither path produces an approved drug. A 503B product meets a higher manufacturing standard, but FDA still has not reviewed it for safety or effectiveness.
How is Ozempic different from a compounded vial?
The Ozempic prescribing information on DailyMed describes exactly what is in the pen. The active ingredient is semaglutide, a human GLP-1 receptor agonist made by yeast fermentation and modified for albumin binding. It comes in three pen strengths: 2 mg/3 mL (delivers 0.25 mg or 0.5 mg), 4 mg/3 mL (delivers 1 mg), and 8 mg/3 mL (delivers 2 mg). Each pen dials a fixed dose. You do not measure anything.
The label also fixes the schedule. Treatment starts at 0.25 mg once weekly for 4 weeks, then moves to 0.5 mg. Further steps to 1 mg and 2 mg each follow at least 4 weeks apart. Our Ozempic dosing schedule guide walks through those steps.
A compounded product usually arrives as a multiple-dose vial with a syringe. The concentration depends on the compounder. The patient draws up the dose in "units" on an insulin syringe. FDA says that design is where many of the problems start.
Why was compounded semaglutide allowed at all?
Federal law lets compounders make versions of a drug that is on FDA's drug shortage list, if certain conditions are met. Semaglutide injection went on that list in 2022, when demand outran supply. During the shortage, 503A pharmacies and 503B facilities could compound copies of semaglutide without FDA enforcement action. Telehealth companies built large compounded programs on that allowance.
What changed when FDA declared the shortage resolved?
On February 21, 2025, FDA announced that the semaglutide shortage was resolved. The agency's policy page for compounders (current as of April 1, 2026) says manufacturer capacity now meets present and projected national demand. FDA then gave compounders a grace period to wind down:
- 503A pharmacies: until April 22, 2025 (60 days).
- 503B outsourcing facilities: until May 22, 2025 (90 days).
A court decision on April 24, 2025 confirmed those dates. Tirzepatide (Mounjaro, Zepbound) went through the same process earlier. Its shortage was declared resolved on December 19, 2024, with grace periods ending February 18, 2025 for 503A and March 19, 2025 for 503B.
After those dates, compounding a product that is "essentially a copy" of Ozempic or Wegovy is outside FDA's policy. The remaining exception is narrow. A prescriber must document that the compounded product contains a change that produces a significant difference for a named patient. FDA also says it does not intend to act against a 503A pharmacy that fills four or fewer such prescriptions in a calendar month. That exception is for individual patients, not for a mass-market product sold by subscription.
What are semaglutide sodium and semaglutide acetate?
This is the part most people miss. Some compounders do not use semaglutide base at all. They use a salt form, semaglutide sodium or semaglutide acetate. FDA's page on unapproved GLP-1 drugs (current as of September 1, 2026) states: "These salt forms are different active ingredients than are used in the approved drugs." FDA says it has no information showing the salts have the same properties as the approved ingredient. It adds that it is "not aware of any lawful basis for their use in compounding."
So a vial labeled "semaglutide" may contain a molecule that has never been tested in a clinical trial. Ozempic's label rests on trials of one specific compound. A salt form is not that compound. If you already use a compounded product, ask the pharmacy in writing which form it used.
What adverse events has FDA seen with compounded semaglutide?
As of May 31, 2026, FDA had received 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide. FDA says those numbers understate the problem, because state-licensed pharmacies have no federal duty to report adverse events.
Dosing errors are the most specific warning. In a July 2024 alert on compounded injectable semaglutide, FDA described patients who gave themselves 5 to 20 times the intended dose. Examples in the alert:
- Patients told to draw 5 units on a U-100 insulin syringe drew 50 units instead.
- A prescriber wrote 25 units instead of 5 units, a fivefold overdose.
- A prescription for 20 units instead of 2 units reached three patients, a tenfold overdose.
- A healthcare provider self-administered a dose 10 times higher than intended.
The causes were confusion between milliliters, milligrams, and units, plus prescribers miscalculating conversions and vials with concentrations that vary from one compounder to the next. Reported effects included severe nausea, severe vomiting, fainting, dehydration, acute pancreatitis, and gallstones. Some patients needed hospital care. FDA also reported prescriptions that started above the labeled dose or stepped up faster than the label allows. For the expected side effect profile of the approved drug, see our side effects management guide.
How do you check whether a pharmacy is legitimate?
The National Association of Boards of Pharmacy (NABP) reviewed a study of 317 online pharmacies. About 42% were selling semaglutide without a valid license and without a prescription. Products bought from sites on NABP's Not Recommended List included one that tested positive for endotoxin. The NABP summary advises buying only from verified, licensed pharmacy websites and checking any seller with the Safe Site Search Tool at safe.pharmacy.
NABP's earlier RogueRx report lists the warning signs: no prescription required, products sold as "research chemicals" or "peptides," and social media sellers who misspell drug names to dodge platform filters. It also notes counterfeit Ozempic pens that contained insulin and caused seizures and severe low blood sugar.
A practical checklist:
- Confirm the pharmacy holds a license from your state board of pharmacy.
- Run the website through NABP's Safe Site Search Tool.
- If the seller claims to be a 503B facility, find it on FDA's registered outsourcing facility list.
- Ask which active ingredient was used: semaglutide base, or a sodium or acetate salt.
- Walk away from any seller that skips the prescription or calls the product a "research peptide."
FDA's BeSafeRx campaign gives the same advice: buy only from state-licensed pharmacies. Our Ozempic cost guide covers those options. For the broader class, including tirzepatide and newer agents, see glp1.md.
The bottom line
Ozempic is one molecule, in a fixed-dose pen, with a label FDA reviewed. A compounded product is unreviewed, may use a different salt form, and puts the dose measurement in your hands. FDA's shortage-based allowance ended in April and May 2025, and as of FDA's September 2026 update the agency still lists 990 adverse event reports and warns against the salt forms. If you use a compounded product, ask the pharmacy what is in the vial and check its license. If you can get the approved drug, that is the version the evidence supports.
Last updated: September 2026. This article is for informational purposes only and does not constitute medical advice. Talk with your prescriber or pharmacist before starting, switching, or stopping any semaglutide product.